1.3.1.2: dihydropyrimidine dehydrogenase (NADP+)
This is an abbreviated version!
For detailed information about dihydropyrimidine dehydrogenase (NADP+), go to the full flat file.
Word Map on EC 1.3.1.2
-
1.3.1.2
-
5-fluorouracil
-
thymidine
-
phosphorylase
-
uridine
-
medicine
-
phosphoribosyltransferase
-
orotate
-
2.4.2.4
-
thymidylate
-
fluoropyrimidine
-
fdurd
-
2.7.1.21
-
beta-ureidopropionase
-
urdpase
-
dihydropyrimidinase
-
beta-alanine
-
drug development
-
analysis
- 1.3.1.2
- 5-fluorouracil
- thymidine
- phosphorylase
- uridine
- medicine
-
phosphoribosyltransferase
- orotate
-
2.4.2.4
- thymidylate
-
fluoropyrimidine
-
fdurd
-
2.7.1.21
- beta-ureidopropionase
- urdpase
- dihydropyrimidinase
- beta-alanine
- drug development
- analysis
Reaction
Synonyms
4,5-dihydrothymine: oxidoreductase, dehydrogenase, dihydrouracil (nicotinamide adenine dinucleotide phosphate), DHPDH, DHPDHase, DHU dehydrogenase, dihydropyrimidine dehydrogenase, dihydrothymine dehydrogenase, Dihydrouracil dehydrogenase, dihydrouracil dehydrogenase (NADP), dihydrouracil dehydrogenase (NADP+), DPD, DPYD, hydropyrimidine dehydrogenase
ECTree
1.3.1.2 dihydropyrimidine dehydrogenase (NADP+)Advanced search results
results (
results (Application
Application on EC 1.3.1.2 - dihydropyrimidine dehydrogenase (NADP+)
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
APPLICATION 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
analysis
-
study on DPD enzyme expression using RT-PCR, immunohistochemistry, enzymatic activity and ELISA. Highest correlation is observed between protein expression measured by ELISA and enzyme activity, correlation of gene expression and ELISA is also significant
drug development
the enzyme is an adjunct target in cancer therapy since it rapidly breaks down the anti-cancer drug 5-fluorouracil and related compounds
medicine
medicine
-
target for inhibitor design to enhance the cytotoxical effect of 5-fluorouracil in tumor cells by inhibiting the DPD activity with 5-fluorouracil as substrate
medicine
-
target for inhibitor design to enhance the cytotoxical effect of 5-fluorouracil in tumor cells by inhibiting the DPD activity with 5-fluorouracil as substrate
medicine
-
rate limiting enzyme for detoxification of exogenous fluoropyrimidines, antitumor drug design
medicine
-
rate limiting enzyme for detoxification of exogenous fluoropyrimidines, antitumor drug design
medicine
-
rate limiting enzyme in catabolic degradation of pyrimidine derivatives, selective inhibition is strategy for design of antitumor, antimicrobial and potentially antiparasitic agents
medicine
-
development of a HPLC method, sufficient, accurate, fast and sensitive to be applied to the analysis of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in plasma and cytoplasmic samples, allowing accurate pharmacokinetic analyses and measurements of dihydropyrimidine dehydrogenase in patients who are candidates for fluoropyrimidine-based chemotherapy without the need of a labeled substrate for enzyme studies
medicine
-
identification of mutants G366A and T768K in healthy Japanese volunteers. G366A results in marked decrease in enzyme affinity to NADPH, reduction of Vmax for 5-fluorouracil degrading activity, T768K leads to rapid loss of enzyme activity
medicine
-
identification of mutations E244V and A551T and splice site mutation IVS11+1G to T in patients with complete loss of enzymic activity
medicine
identification of mutations E244V and A551T and splice site mutation IVS11+1G to T in patients with complete loss of enzymic activity
medicine
-
uracil breath test breath 13CO2 pharmacokinetics parallel plasma [2-13C]uracil and [2-13C]dihydrouracil pharmacokinetics and are an accurate measure of interindividual variation in enzyme activity. Data support the use of uracil breath test to identify enzyme deficiency before 5-fluorouracil-based therapy
